Pharmaceutical - Nexavar

Filter

Current filters:

Nexavar

Popular Filters

1 to 25 of 34 results

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

Bayer’s Nexavar cleared in Japan for differentiated thyroid cancer

20-06-2014

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved German pharma major Bayer’s oral…

BayerJapanNexavarOncologyPharmaceuticalRegulation

EMA recommends extending use of Bayer’s Nexavar

27-04-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

BayerEuropeNexavarOncologyPharmaceuticalRegulation

Transgene, Lee’s Pharma and SillaJen confirm clinical development plan for Pexa-Vec

27-03-2014

France’s Transgene, Hong Kong-based Lee’s Pharmaceutical and South Korea’s SillaJen have unveiled…

BayerLee's PharmaceuticalNexavarOncologyPexa-VecPharmaceuticalResearchSillaJenTransgene

Nexavar disappoints in Ph III liver cancer study

Nexavar disappoints in Ph III liver cancer study

11-03-2014

German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that…

AmgenBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Liver cancer market to nearly treble in size to $1.4 billion by 2019

Liver cancer market to nearly treble in size to $1.4 billion by 2019

13-11-2013

The value of the hepatocellular cancer (HCC) market is set to grow by a massive 172% and hit $1.4 billion…

BayerEuropeMarkets & MarketingNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalResearchUSA

Nexavar gains FDA priority review for thyroid cancer sNDA

27-08-2013

German drug major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), which has just agreed…

BayerBiotechnologyNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

BioAlliance updates on Livatag development

14-05-2013

French orphan cancer drug developer BioAlliance Pharma (Euronext Paris: BIO) says that the International…

BioAlliance PharmaLivatagNexavarOncologyPharmaceuticalResearch

Indian patent appeal board upholds compulsory license on Bayer's Nexavar

05-03-2013

After much delay, the verdict into German pharmaceutical major Bayer's (BAYN: DE) appeal against the…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

AVEO/Astellas' kidney cancer drug tivozanib fails to beat Nexavar

14-02-2013

US biotech AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TYO: 4503) have announced…

Astellas PharmaAVEO OncologyBayerBiotechnologyNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchtivozanib

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

Positive Ph III results for Bayer's Nexavar in thyroid cancer

03-01-2013

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) this morning revealed…

BayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Nexavar use in Chinese patients nearly doubled in 2012

19-12-2012

Use of Nexavar (sorafenib, from Bayer [BAYN: DE] and Onyx Pharmaceuticals) has nearly doubled in first-line…

AlimtaAsia-PacificBayerBiotechnologyEli LillyMarkets & MarketingNexavarOncologyPharmaceutical

India's IPAB rejects Bayer's "stay petition" regarding Nexavar

18-09-2012

Over the weekend, the Intellectual Property Appellate Board (IPAB) of Chennai, India, has dismissed the…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Bayer attempts to block generic Nexavar in India again slammed by MSF

04-09-2012

German drug major Bayer (BAYN: DE) yesterday headed to India's Intellectual Property Appellate Board…

Asia-PacificBayerGenericsLegalNexavarOncologyPatentsPharmaceutical

Indian hearings on Bayer Nexavar compulsory license delayed

22-08-2012

India's Intellectual Property Appellate Board (IPAB) in Chennai has postponed hearing the appeal by German…

Asia-PacificBayerGenericsLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Adding Tarceva to Nexavar no better than Nexavar alone for liver cancer

23-07-2012

A Phase III trial evaluating the efficacy and safety of the addition of Roche's Tarceva (erlotinib) tablets…

Astellas PharmaBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearchTarceva

Bristol-Myers brivanib fails in Ph III liver cancer trial

20-07-2012

US drug major Bristol-Myers Squibb (NYSE: BMY) yesterday reported results of the Phase III BRISK-FL clinical…

Bristol-Myers SquibbbrivanibNexavarOncologyPharmaceuticalResearch

1 to 25 of 34 results

Back to top